440 related articles for article (PubMed ID: 23180565)
1. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
Saddoughi SA; Gencer S; Peterson YK; Ward KE; Mukhopadhyay A; Oaks J; Bielawski J; Szulc ZM; Thomas RJ; Selvam SP; Senkal CE; Garrett-Mayer E; De Palma RM; Fedarovich D; Liu A; Habib AA; Stahelin RV; Perrotti D; Ogretmen B
EMBO Mol Med; 2013 Jan; 5(1):105-21. PubMed ID: 23180565
[TBL] [Abstract][Full Text] [Related]
2. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
Oaks JJ; Santhanam R; Walker CJ; Roof S; Harb JG; Ferenchak G; Eisfeld AK; Van Brocklyn JR; Briesewitz R; Saddoughi SA; Nagata K; Bittman R; Caligiuri MA; Abdel-Wahab O; Levine R; Arlinghaus RB; Quintas-Cardama A; Goldman JM; Apperley J; Reid A; Milojkovic D; Ziolo MT; Marcucci G; Ogretmen B; Neviani P; Perrotti D
Blood; 2013 Sep; 122(11):1923-34. PubMed ID: 23926298
[TBL] [Abstract][Full Text] [Related]
3. FTY720 induces autophagy-related apoptosis and necroptosis in human glioblastoma cells.
Zhang L; Wang H; Ding K; Xu J
Toxicol Lett; 2015 Jul; 236(1):43-59. PubMed ID: 25939952
[TBL] [Abstract][Full Text] [Related]
4. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
Cristóbal I; Manso R; Rincón R; Caramés C; Senin C; Borrero A; Martínez-Useros J; Rodriguez M; Zazo S; Aguilera O; Madoz-Gúrpide J; Rojo F; García-Foncillas J
Mol Cancer Ther; 2014 Apr; 13(4):938-47. PubMed ID: 24448818
[TBL] [Abstract][Full Text] [Related]
5. FTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels.
Chen L; Luo LF; Lu J; Li L; Liu YF; Wang J; Liu H; Song H; Jiang H; Chen SJ; Luo C; Li KK
PLoS One; 2014; 9(7):e103033. PubMed ID: 25050888
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma.
Enjoji S; Yabe R; Fujiwara N; Tsuji S; Vitek MP; Mizuno T; Nakagawa T; Usui T; Ohama T; Sato K
J Vet Med Sci; 2015 Nov; 77(11):1451-6. PubMed ID: 26062569
[TBL] [Abstract][Full Text] [Related]
7. Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A.
Zonta F; Pagano MA; Trentin L; Tibaldi E; Frezzato F; Trimarco V; Facco M; Zagotto G; Pavan V; Ribaudo G; Bordin L; Semenzato G; Brunati AM
Blood; 2015 Jun; 125(24):3747-55. PubMed ID: 25931585
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
[TBL] [Abstract][Full Text] [Related]
9. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling.
Mukhopadhyay A; Saddoughi SA; Song P; Sultan I; Ponnusamy S; Senkal CE; Snook CF; Arnold HK; Sears RC; Hannun YA; Ogretmen B
FASEB J; 2009 Mar; 23(3):751-63. PubMed ID: 19028839
[TBL] [Abstract][Full Text] [Related]
10. Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.
Mukhopadhyay A; Tabanor K; Chaguturu R; Aldrich JV
Cancer Biol Ther; 2013 Oct; 14(10):962-72. PubMed ID: 24025258
[TBL] [Abstract][Full Text] [Related]
11. The NMR-based characterization of the FTY720-SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET-PP2A interaction.
De Palma RM; Parnham SR; Li Y; Oaks JJ; Peterson YK; Szulc ZM; Roth BM; Xing Y; Ogretmen B
FASEB J; 2019 Jun; 33(6):7647-7666. PubMed ID: 30917007
[TBL] [Abstract][Full Text] [Related]
12. Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity.
Pippa R; Dominguez A; Christensen DJ; Moreno-Miralles I; Blanco-Prieto MJ; Vitek MP; Odero MD
Leukemia; 2014 Sep; 28(9):1915-8. PubMed ID: 24781014
[No Abstract] [Full Text] [Related]
13. Ceramide in the prostate.
Dent P
Cancer Biol Ther; 2013 Oct; 14(10):881-2. PubMed ID: 24025252
[TBL] [Abstract][Full Text] [Related]
14. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.
Farrell AS; Allen-Petersen B; Daniel CJ; Wang X; Wang Z; Rodriguez S; Impey S; Oddo J; Vitek MP; Lopez C; Christensen DJ; Sheppard B; Sears RC
Mol Cancer Res; 2014 Jun; 12(6):924-39. PubMed ID: 24667985
[TBL] [Abstract][Full Text] [Related]
15. Receptor-interacting Ser/Thr kinase 1 (RIPK1) and myosin IIA-dependent ceramidosomes form membrane pores that mediate blebbing and necroptosis.
Nganga R; Oleinik N; Kim J; Selvam SP; De Palma R; Johnson KA; Parikh RY; Gangaraju V; Peterson Y; Dany M; Stahelin RV; Voelkel-Johnson C; Szulc ZM; Bieberich E; Ogretmen B
J Biol Chem; 2019 Jan; 294(2):502-519. PubMed ID: 30420430
[TBL] [Abstract][Full Text] [Related]
16. A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity.
Vicente C; Arriazu E; Martínez-Balsalobre E; Peris I; Marcotegui N; García-Ramírez P; Pippa R; Rabal O; Oyarzábal J; Guruceaga E; Prósper F; Mateos MC; Cayuela ML; Odero MD
Cancer Lett; 2020 Jan; 468():1-13. PubMed ID: 31593801
[TBL] [Abstract][Full Text] [Related]
17. Synergic effect of OP449 and FTY720 on oral squamous cell carcinoma.
Goto RN; Sobral LM; Stringhetta-Padovani K; Garcia CB; da Silva G; Vitek MP; Leopoldino AM
Eur J Pharmacol; 2020 Sep; 882():173268. PubMed ID: 32569675
[TBL] [Abstract][Full Text] [Related]
18. Isoliensinine induces dephosphorylation of NF-kB p65 subunit at Ser536 via a PP2A-dependent mechanism in hepatocellular carcinoma cells: roles of impairing PP2A/I2PP2A interaction.
Shu G; Zhang L; Jiang S; Cheng Z; Wang G; Huang X; Yang X
Oncotarget; 2016 Jun; 7(26):40285-40296. PubMed ID: 27244888
[TBL] [Abstract][Full Text] [Related]
19. SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A.
Hung MH; Wang CY; Chen YL; Chu PY; Hsiao YJ; Tai WT; Chao TT; Yu HC; Shiau CW; Chen KF
Oncotarget; 2016 Jan; 7(1):638-55. PubMed ID: 26575017
[TBL] [Abstract][Full Text] [Related]
20. Fingolimod targeting protein phosphatase 2A differently affects IL-33 induced IL-2 and IFN-γ production in CD8(+) lymphocytes.
Ottenlinger F; Schwiebs A; Pfarr K; Wagner A; Grüner S; Mayer CA; Pfeilschifter JM; Radeke HH
Eur J Immunol; 2016 Apr; 46(4):941-51. PubMed ID: 26683421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]